ClinicalTrials.gg

Program

sacituzumab drozuntecan

Its studies are mostly in Squamous Cell Carcinoma of Head and Neck, led by DualityBio.

Furthest: phase 2, since Jun 14, 20222 company-led studies, 2 open or runningNext primary completion: Aug 13, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
DualityBio22 open or runningphase 2since Jun 14, 2022Jun 14, 2022Aug 13, 2027phase 2 · NCT05438329

Also a collaborator on its studies: BioNTech.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 14, 2022First study: phase 2 study in Advanced Solid TumorFirst studyNCT05438329 · 1,123 enrolled · United States, China, Puerto Rico
  2. Apr 9, 2025Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06953089 · 750 planned · United States, Australia, China and more

Ahead

  1. Aug 13, 2027Primary completion: phase 2 study in Advanced Solid TumorNCT05438329
  2. Jun 30, 2030Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06953089

TargetBeta

TACSTD2 →read by rule
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) covalently ”NCIt, by rule

Other programs on TACSTD2

ProgramCompanyFurthest phaseStudies
sacituzumab govitecanruleGilead Sciencesphase 430
sacituzumab tirumotecanMerckphase 350
datopotamab deruxtecanruleAstraZenecaphase 328
JSKN016ruleAlphamab Oncologyphase 35
Anti-TROP2 Antibody-drug Conjugate ESG401ruleQilu Pharmaceuticalphase 33
Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036CruleMinghui Pharmaceuticalphase 23
Anti-TROP-2 Antibody-drug Conjugate OBI-902ruleobi-pharma-incphase 21
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleavenzo-therapeutics-incphase 21
Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998ruleAstellas Pharmaphase 21
JSKN016HCruleAlphamab Oncologyphase 11
KH815ruleChengdu Kanghong Pharmaceutical Groupphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06953089Squamous Cell Carcinoma of Head and Neck · United States, Australia, China and more2RecruitingJun 30, 2030750
NCT05438329Advanced Solid Tumor · United States, China, Puerto Rico2Active, not recruitingAug 13, 20271,123

How it is read

Names in the registry

  • “DB-1305/BNT325”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.